Loading patent…
AssigneeRandox Laboratories Limited
InventorsMark Ruddock, John Lamont, Stephen Fitzgerald, Kathleen Williamson
Estimating the term…
The present invention provides a method for detecting the presence or risk of bladder cancer in a female patient comprising the steps of detecting the presence of a panel of biomarkers in a sample isolated from a female patient, said panel of biomarkers comprising IL-13 and IL-12p70 and one or more biomarkers selected from BTA, Midkine, PAI-1/tPA, 8OHdG, CEA, CK18, Clusterin, Creatinine, CXCL16, Cystatin B, Cystatin C, d-Dimer, EGF, FAS, HAD, IL-1a, IL-1b, IL-4, IL-6, IL-7, IL-8, MCP-1, Microalbumin, MMP9NGAL, MMP9TIMP1, NGAL, NSE, Progranulin, TUP, TGFB1, Thrombomodulin, sTNFR1, TPA, VEGF and Triglycerides and/or the concentration of albumin/microalbumin/protein and creatinine expressed as an albumin:creatinine ratio in a sample isolated from a female patient; and assessing the results and comparing them to a normal control wherein an elevated presence of the biomarker compared to a normal control indicates the presence or risk of cancer in the patient from whom the sample is isolated.
A method for the detection of or the risk of bladder cancer in a female patient comprising the steps of
A solid support material comprising binding molecules attached thereto, said binding molecules having affinity specific for IL-13 and, separately, IL-12p70, with the binding molecules for each being in discrete locations on the support material.
A method for the detection of or the risk of bladder cancer in a female patient comprising the steps of
Dependencies are inferred from the claim text.